Research Article

A New Hypoxia-Related Prognostic Risk Score (HPRS) Model Was Developed to Indicate Prognosis and Response to Immunotherapy for Lung Adenocarcinoma

Figure 6

The role of HPRS in predicting the immunotherapy response and chemotherapy effect of LUAD. (a): The normalized expression (Log2 (FPKM + 1)) of immune checkpoints in high HPRS and low HPRS groups. (b): In TCGA (left), GSE31210 (center), and GSE50081 (right), the difference of TIDE score between high HPRS group and low HPRS group. (c): Estimated IC50 of paclitaxel, cisplatin, docetaxel, and vinorelbine in different HPRS groups. (d): Correlation between HPRS and estimated IC50 of paclitaxel, cisplatin, docetaxel, and vinorelbine. , , , .
(a)
(b)
(c)
(d)